Alicia Morgans: Hi. My name is Alicia Morgans, and I'm a GU medical oncologist at Dana-Farber Cancer Institute in Boston in the U.S. I'm so excited to have here with me today Dr. Aurelius Omlin, who is a GU medical oncologist in St. Gallen, Switzerland and is one of the leads of the APCCC Consensus Prostate Cancer Conference. Thank you so much for being here with me today, Dr. Omlin.

Aurelius Omlin: Thank you, Alicia, for having me talk about the APCCC, as [inaudible 00:00:28] likes to call it.

Alicia Morgans: Yes, I'm so excited that this is one of the bi-annual events that we look forward to. Really hearing from experts, and hearing how the experts vote on all of the questions in the gray area that really drive us a bit crazy and, I think, are what really matters to patients when they're sitting with us in clinic. Can you tell us, what was the reason that you and Dr. Gillessen put together this APCCC in the first place?

Aurelius Omlin: That's a good question. The reason behind APCCC was really that in 2014 when we initiated the conference, we thought about all the new options that, at that point, mainly in CRPC, became available. But then we already knew that in MHSPC, hormone-sensitive metastatic prostate cancer, a lot of trials were running and we knew that there will be a lot of open questions, areas that were not addressed by the trials or data that are maybe interpreted in different ways. So we wanted to address what we call areas of uncertainties or whether it's lack of data or conflicting interpretation of the data. And that's why we initiated the conference, which should have happened really bi-annually last year in 2021. And we had only a small virtual version because of COVID and we hope really very much that in April we can all meet live in Lugano.

Alicia Morgans: Wonderful. So really this conference is happening April 28th through 30th in Lugano, Switzerland where we're going to have experts from all around the world, join you and the team to discuss these really exciting areas. And here we can see just a sampling of where all of these folks are coming from. And of course by that time, they will have already voted on the gray areas of data and we'll be able to reveal the results and kind of show the consensus or lack thereof for each of these questions. Is that true?

Aurelius Omlin: That's absolutely true. We started in 2015 with a bit more than 30 experts and now expanded. And this time not everyone will be physically present, but we expanded the panel to more than 100 experts. So some of them will join virtually, but they will all have been involved in the development of the questions. And at the moment actually the voting is going on and we will have the results ready after each session. So we usually have several topics that we address from locally advanced to biochemically recurrent to oligometastatic disease, metastatic hormone-sensitive CRPC, and other issues. And then after each of these topics where we have lectures and debates, we will have a selection of the questions that the people voted on that we present and discuss.

Alicia Morgans: Wonderful. And I bet we might even once or twice hear the cowbell when somebody goes over time and time is very important when you present in Switzerland. So as you think about this and have to give someone sort of the final message, and of course they shouldn't forget the translational science symposium which is happening on the day before, what would your final message be to viewers?

Aurelius Omlin: I think if you're involved in the care of men with advanced prostate cancer, then APCCC is definitely the place to be. We won't have new data. So it's not like an [inaudible 00:03:42] or expo where you have a lot of additional new information from oral presentations to abstracts. But we have really what is the current state of the art? Where do we have evidence? Where do we have lack of evidence and how do we make decisions in daily practice? It's really, I think, based on what you need to know when you sit with a patient in front of you.

Alicia Morgans: Absolutely. I think that your comment says it all. APCCC is absolutely the place to be. Thank you so much for your time and for putting this together for us yet again.

Aurelius Omlin: Thank you, Alicia.